Lung cancer is the most common cause of cancer-related deaths in the United States. The curerate for patients with advanced lung cancer remains low and has not changed significantly for the last 30years. A better understanding of the signaling pathways important in driving and maintaining the malignantstate is important for continued progress in the treatment of patients with lung cancer. The Notch family ofreceptors has been demonstrated to be important both in cell fate determination and tumorigenesis.Despite the increasing role of Notch pathway in human cancers, very little was known about the role ofNotch3 and its effectors in lung cancers. We were the first to link dysregulation of the Notch3 pathway tohuman lung cancer. We demonstrated that NotchS is highly expressed in 40% of all resected lung cancersand that, in the developing lung, constitutive activation of NotchS results in inhibition of terminaldifferentiation of pneumocytes. Furthermore, we have shown that inhibiting this pathway in human lungtumors results in the loss of the malignant phenotype in vitro and in vivo using xenograft models. Thisantitumor effect is enhanced in the presence of low serum and in combination with an EGFr tyrosine kinaseinhibitor. Taken together, our data support an important role for NotchS receptor and its interaction with theEGF and ras pathways in lung cancer. In addition, we now have strong evidence from both in vitro and invivo studies that Notch signaling can be effectively blocked by inhibiting the required receptor processingwith a y-secretase inhibitor from Merck Inc. & Co., currently in Phase I human clinical trials. In this proposal, we will further develop preclinical and clinical models to optimize these strategiesusing Y-secretase inhibitor for human clinical testing. Furthermore, we also propose to develop biologicallyactive, recombinant antibody targeting NotchS. Both these approaches represent novel, therapeuticstrategies in the treatment of patients with lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090949-06A1
Application #
7316644
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-09-26
Budget End
2008-03-31
Support Year
6
Fiscal Year
2007
Total Cost
$201,889
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Codreanu, Simona G; Hoeksema, Megan D; Slebos, Robbert J C et al. (2017) Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma. J Proteome Res 16:3266-3276
Udyavar, Akshata R; Wooten, David J; Hoeksema, Megan et al. (2017) Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity. Cancer Res 77:1063-1074
Uzhachenko, Roman; Shanker, Anil; Dupont, Geneviève (2016) Computational properties of mitochondria in T cell activation and fate. Open Biol 6:
Pulliam, Stephanie R; Pellom Jr, Samuel T; Shanker, Anil et al. (2016) Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine 84:74-87
Edmonds, Mick D; Boyd, Kelli L; Moyo, Tamara et al. (2016) MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. J Clin Invest 126:349-64
Boutaud, Olivier; Sosa, I Romina; Amin, Taneem et al. (2016) Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. Cancer Prev Res (Phila) 9:855-865
Pulliam, Stephanie R; Uzhachenko, Roman V; Adunyah, Samuel E et al. (2016) Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett 169:61-72
Whang, Y M; Park, S I; Trenary, I A et al. (2016) LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene 35:856-66
Hassanein, Mohamed; Hight, Matthew R; Buck, Jason R et al. (2016) Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Mol Imaging Biol 18:18-23
de Aquino, Maria Teresa P; Malhotra, Anshu; Mishra, Manoj K et al. (2015) Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 166:117-33

Showing the most recent 10 out of 217 publications